ABBOTT LABORATORIES (NYSE: ABT)

Click Here to Add This Stock To Your Watchlist
Click Here to Trade This Stock
Click Here to Trade Option
0.68 (1.28%)
$53.64
Real-time: $53.64 0.68 (1.28%) 12:00:00 AM ET Turn On
You need to upgrade your Flash Player to view the graph.
View by Date Range:
Are you Bullish or Bearish on ABT?
Investors are 91% Bullish and 9% Bearish on ABT
Key Stats
Market Cap
81.92 B
Diluted EPS (TTM)
3.32
P/E Ratio (TTM)
14.4
52-Week High Price
57.39
52-Week Low Price
41.27
Avg Volume (3 Mo.)
5.00 M
Beta
0.23
Shares
1546.74 M
Dividend Rate ($)
1.60
Dividend Rate (%)
3.00
12 Mo. Price Change : N/A
  Similar Companies  
NameMost Recent PriceToday's ChangeMarket Cap 
JOHNSON & JOHNSON (JNJ) $62.31$0.37(0.60%)172.25 B
PFIZER INC (PFE) $18.36$0.25(1.38%)146.14 B
NOVARTIS AG ADS (NVS) $53.13$0.16(0.30%)120.69 B
GLAXOSMITHKLINE PLC (GSK) $41.53$0.06(0.14%)117.39 B
SANOFI-AVENTIS ADS (SNY) $37.67$0.01(0.03%)99.14 B
MERCK & COMPANY; INC. (MRK) $36.46$1.13(3.20%)74.52 B
ASTRAZENECA PLC (AZN) $44.82$0.37(0.82%)65.44 B
AMGEN INC (AMGN) $55.38$0.68(1.21%)56.74 B
TEVA PHARMACEUTICAL LTD (TEVA) $52.72$0.32(0.60%)48.37 B
BRISTOL-MYERS SQUIBB CO (BMY) $24.46$0.43(1.79%)47.60 B
arrow
Answering The Vytorin Question
Merck scores a PR win at a cardiology conference, but that doesn't mean its cholesterol drugs are effective.

Forbes.com 11/18/2009
arrow
Trading Outlook for Vermillion Inc. Issued by StockPreacher.com
Trading Outlook for Vermillion Inc. Issued by StockPreacher.com

by GlobeNewswire 11/16/2009
arrow
Another Vytorin Mess For Merck
A new study, though flawed, inflicts more damage on the company's Zetia and Vytorin cholesterol pills.

Forbes.com 11/15/2009
arrow
Abbott Laboratories (ABT) NewsBite - ABT Rises on Outperform Rating
Abbott Laboratories (NYSE: ABT) opened at $53.39. So far today, the stock has hit a low of $53.01 and a high of $53.80. ABT is now trading at $53.23, down $0.04 (-0.08%). Over the last 52 weeks the stock has ranged from a low of $41.27 to a high of $57.39. Wedbush Morgan initiated ABT at Outperform this morning, giving the stock a $62 pri...

At Market Intelligence Center 11/12/2009
arrow
Targeting Tysabri
The drug's inventor believes a new test might identify people who are less at risk for a deadly side effect.

Forbes.com 10/27/2009
Sponsored Links
MARKETPLACE
TRADING CENTER
My Profile | Portfolio | Trading | Ranking | Games | Help | Resources | Contact | Corporate | Financial Edge
Copyright © 2009 Investopedia ULC. All Rights Reserved | Privacy Policy | Terms of Use | Dictionary Licensing | Advertise on Investopedia | About Us
Stock News In Your Inbox | RSS
Xignite Stock Quotes from BATS Exchange
COLOSIM2